Evidence map›Paper›PMID 32698852›Full record

ArticleBMC research notes2020

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours.

Sally M Hunter, Genevieve V Dall, Maria A Doyle, Richard Lupat, Jason Li, Prue Allan, Simone M Rowley, David Bowtell, AOCS, Ian G Campbell and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sally M HunterCancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Genevieve V DallCancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Maria A DoyleBioinformatics Core Facility Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Richard LupatBioinformatics Core Facility Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Jason LiBioinformatics Core Facility Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Prue AllanAnatomical Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Simone M RowleyCancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia.
David BowtellCancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia.
AOCS
Ian G CampbellCancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Kylie L GorringeCancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia. kylie.gorringe@petermac.org.ORCID http://orcid.org/0000-0001-5681-2022
Peter MacCallum Cancer Centre · AUThe University of Melbourne · AU

Funding

National Health and Medical Research Council 628630
6 · The paper itself

Abstract

objectiveOvarian fibromas and adenofibromas are rare ovarian tumours. They are benign tumours composed of spindle-like stromal cells (pure fibroma) or a mixture of fibroblast and epithelial components (adenofibroma). We have previously shown that 40% of benign serous ovarian tumours are likely primary fibromas due to the neoplastic alterations being restricted to the stromal compartment of these tumours. We further explore this finding by comparing benign serous tumours to pure fibromas.

resultsPerforming copy number aberration (CNA) analysis on the stromal component of 45 benign serous tumours and 8 pure fibromas, we have again shown that trisomy of chromosome 12 is the most common aberration in ovarian fibromas. CNAs were more frequent in the pure fibromas than the benign serous tumours (88% vs 33%), however pure fibromas more frequently harboured more than one CNA event compared with benign serous tumours. As these extra CNA events observed in the pure fibromas were unique to this subset our data indicates a unique tumour evolution. Gene expression analysis on the two cohorts was unable to show gene expression changes that differed based on tumour subtype. Exome analysis did not reveal any recurrently mutated genes.

Indexed as

FibromaOvarian NeoplasmsDNA Copy Number VariationsExomeFemaleHumansTrisomyAdenofibromaCopy number aberrationsCystadenofibromaCystadenomasExome sequencingGene expressionMicroarraysOvarian fibroma

Identifiers

PMID32698852
PMCPMC7376903
OpenAlexW3045384800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.